Approvals
Decisions by the FDA and other regulators on new drugs, biologics and devices.
Stories
-
FDA approves pimicotinib for adults with symptomatic tenosynovial giant cell tumor
The FDA approved pimicotinib (Pimjetmi) on November 10, 2026, after an overall response rate of 56% versus 3.2% on placebo at Week 25. For adults with symptomatic TGCT, an approved kinase inhibitor now exists.
-
Abbisko's PIMJETMI receives U.S. FDA approval for TGCT
The U.S. FDA approved PIMJETMI as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The approval follows earlier approvals in China, Canada and Switzerland and is based on the Phase III MANEUVER study showing a 56% objective response rate versus 3% for placebo.
-
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.
-
FDA approves Sunharbo for secondary stroke prevention
The FDA approved Sunharbo (asundexian) 50 mg tablets on November 09, 2026 for adults at high risk of stroke after a mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA. The OCEANIC-STROKE phase 3 study enrolled 12,327 participants and found Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26 % compared to placebo over a median treatment of 14.2 months.
-
Johnson & Johnson FDA grants accelerated approval for RYBREVANT FASPRO in head and neck cancer
The FDA granted accelerated approval for RYBREVANT FASPRO as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval was based on the Phase 1b/2 OrigAMI-4 trial, in which the confirmed overall response rate was 42 percent per blinded independent central review.
-
FDA grants pembrolizumab traditional approval for TMB-H solid tumors, ORR 36 percent
The FDA converted pembrolizumab's accelerated approval in TMB-H solid tumors to traditional approval on October 16, 2026, citing an objective response rate of 36 percent in 220 patients. The approval defines TMB-H as 13 mut/Mb or higher.
-
FDA approves pembrolizumab or Keytruda Qlex for TMB-H solid tumors
On October 16, 2026, the FDA granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors defined as ≥13 mutations/megabase. The approval converts the prior accelerated approval and amends the TMB-H definition to ≥13 mut/Mb, as efficacy was not confirmed in patients with TMB of 10 to <13 mut/Mb.
-
FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer
On October 8, 2026, the FDA approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The approval also covers Tecentriq Hybreza for patients 12 years of age and older who weigh 40 kg or greater.
-
FDA grants accelerated approval to Rybrevant Faspro for head and neck squamous cell carcinoma; ORR 42 percent
The FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and an anti-PD-(L)1 antibody; the overall response rate was 42 percent in 102 patients.
-
FDA approves RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval to RYBREVANT FASPRO, a co-formulated amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.
-
Johnson & Johnson announces FDA approval of RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval is based on a 42 percent overall response rate (95 percent CI, 32-52 percent) from the Phase 1b/2 OrigAMI-4 trial.
-
FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for HNSCC
On November 5, 2026 the FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic HNSCC who progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval is based on an overall response rate of 42% (95% CI: 32%, 52%) in 102 patients, and the product is not indicated for HPV-associated oropharyngeal squamous cell carcinoma.